Detalhe da pesquisa
1.
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Target Oncol
; 18(5): 667-684, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37713090
2.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(4): 433-439, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749004
3.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(5): 609, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913648